These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 22180724)

  • 21. Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?
    Holmes JA; Desmond PV; Thompson AJ
    J Viral Hepat; 2012 Oct; 19(10):677-84. PubMed ID: 22967098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
    Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM
    AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C.
    Behnava B; Sharafi H; Keshvari M; Pouryasin A; Mehrnoush L; Salimi S; Karimi Elizee P; Ghazimoghaddam M; Alavian SM
    Hepat Mon; 2016 Jan; 16(1):e32703. PubMed ID: 27110259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C.
    Shahid I; Ibrahim MM
    Curr Mol Med; 2018; 18(7):409-435. PubMed ID: 30608042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
    Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.
    Grebely J; Hellard M; Applegate T; Petoumenos K; Yeung B; Feld JJ; Rawlinson W; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews GV;
    AIDS; 2012 Aug; 26(13):1653-61. PubMed ID: 22555168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Tada T; Kawaguchi T; Murakami Y; Matsuda F
    J Med Virol; 2011 Jul; 83(7):1203-11. PubMed ID: 21567424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
    Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
    Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patients.
    Bokharaei-Salim F; Salehi-Vaziri M; Sadeghi F; Esghaei M; Monavari SH; Alavian SM; Fakhim S; Keyvani H
    Hepat Mon; 2016 May; 16(5):e35597. PubMed ID: 27313635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
    Pawlotsky JM; Flisiak R; Sarin SK; Rasenack J; Piratvisuth T; Chuang WL; Peng CY; Foster GR; Shah S; Wedemeyer H; Hézode C; Zhang W; Wong KA; Li B; Avila C; Naoumov NV;
    Hepatology; 2015 Oct; 62(4):1013-23. PubMed ID: 26118427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL28B polymorphisms of both recipient and donor cooperate to influence IFN treatment response in HCV recurrence after liver transplantation, but IL28B SNPs of the recipient play a major role in IFN-induced blocking of HCV replication.
    Barbera F; Russelli G; Pipitone L; Pietrosi G; Corsale S; Vizzini G; Gridelli B; Conaldi PG
    New Microbiol; 2015 Apr; 38(2):201-10. PubMed ID: 25938745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.
    Naik GS; Tyagi MG
    J Clin Exp Hepatol; 2012 Mar; 2(1):42-54. PubMed ID: 25755405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy.
    Ghanem SE; Elsabaawy M; Shebl N; Abdelsameea E; Othman W; El-Bassal FI; Elgedawy GA; Elsabaawy DM; Helal ML
    Expert Rev Anti Infect Ther; 2020 Sep; 18(9):947-954. PubMed ID: 32419526
    [No Abstract]   [Full Text] [Related]  

  • 34. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
    Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of SNPs in interferon receptor genes in chronic hepatitis C with response to combined therapy of interferon and ribavirin.
    Heidari Z; Shahzamani K; Ghanbari R; Tahamsebifar A
    Acta Med Iran; 2014; 52(10):740-7. PubMed ID: 25369007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection.
    Neukam K; Caruz A; Rivero-Juárez A; Barreiro P; Merino D; Real LM; Herrero R; Camacho A; Soriano V; Di Lello FA; Macías J; Rivero A; Pineda JA
    AIDS; 2013 Nov; 27(17):2715-24. PubMed ID: 23842134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Synopsis of Hepatitis C Virus Treatments and Future Perspectives.
    Medina C; García AH; Crespo FI; Toro FI; Mayora SJ; De Sanctis JB
    Curr Issues Mol Biol; 2023 Oct; 45(10):8255-8276. PubMed ID: 37886964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Host genetics.
    Macías J; Vispo E; Pineda JA; Soriano V
    Curr Opin HIV AIDS; 2011 Nov; 6(6):491-500. PubMed ID: 21918436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-ribavirin.
    Ramos JA; Ramos AL; Hoffmann L; Perez Rde M; Coelho HS; Urményi TP; Silva R; Rondinelli E; Villela-Nogueira CA
    Mem Inst Oswaldo Cruz; 2012 Nov; 107(7):888-92. PubMed ID: 23147144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.